Thermogenesis (KOOL) 0.88 $KOOL
Cesca Therapeutics FQ2 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 9:24AM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics' (KOOL) on CEO Robin Stracey Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 8:37PM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:11PM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics Reports Second Quarter Fiscal 2015 Results
GlobeNewswire - Thu Feb 12, 3:00PM CST
Company to Provide an Update on the Status of Its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients With Critical Limb Ischemia
KOOL: 0.88 (-0.14)
Cesca Therapeutics Announces Approval of Its MarrowXpress(TM) System in India
GlobeNewswire - Wed Feb 11, 9:56AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has received approval from the India Drug Controller General ("DCGI"
for the import and commercialization of its MarrowXpress ("MXP" System in India.
KOOL: 0.88 (-0.14)
Cesca Therapeutics to Announce Second Quarter Fiscal 2015 Results on February 12, 2015
GlobeNewswire - Wed Feb 11, 9:56AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal second quarter ended December 31, 2014, on Thursday, February 12, 2015.
KOOL: 0.88 (-0.14)
Cesca Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 09, 8:30AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today that the Company will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
KOOL: 0.88 (-0.14)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.88 (-0.14), PSTI: 2.91 (+0.01)
Cesca Therapeutics to Present at Biotech Showcase in San Francisco on January 13, 2015
GlobeNewswire - Thu Jan 08, 5:00AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the Biotech Showcase(TM) 2015 on Tuesday, January 13th at 10:00 AM PT (1:00 PM ET).
KOOL: 0.88 (-0.14)
Time in the Market, Not Timing the Market: Featured Research on Rite Aid, American Homes 4 Rent, Perfect World, Foamix, and Cesca
PR Newswire - Mon Jan 05, 7:45AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Rite Aid (NYSE: RAD), American Homes 4 Rent (NYSE: AMH), Perfect World (NASDAQ: PWRD), Foamix (NASDAQ: FOMX), and Cesca (NYSE: KOOL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KOOL: 0.88 (-0.14), AMH: 16.58 (-0.10), FOMX: 9.01 (-0.03), PWRD: 18.95 (+0.02), RAD: 8.34 (+0.25)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 0.88 (-0.14), BLDP: 2.66 (-0.26), PBR: 6.98 (+0.44), LNCO: 12.30 (+0.28), KITE: 62.59 (+0.82), NRX: 6.67 (-0.14), LINE: 12.94 (+0.40), PWRD: 18.95 (+0.02), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Cesca not quite there on Phase 3 CLI trial application
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 6:14AM CST
KOOL: 0.88 (-0.14)
Cesca Receives Feedback From the FDA on Its Pivotal Investigational Device Exemption ("IDE" Application for Treating Critical Limb Ischemia ("CLI"
GlobeNewswire - Fri Jan 02, 4:59AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that it has received a letter from the U.S. Food and Drug Administration responding to the Company's investigational device exemption ("IDE" application for its pivotal CLIRST III clinical trial. The IDE application, filed on November 20, 2014, sought approval to begin a pivotal, randomized, placebo-controlled study of 224 late stage CLI patients at up to 60 clinical sites in the United States and India. In its letter, the FDA noted several deficiencies in the Company's submission, requesting, among other things, additional information on characterization of the output of the SurgWerks(TM) - CLI and VXP system, a plan for testing device output for conformity to predefined intra-operative release criteria prior to administration, modifications to the management of potential adverse events and a strengthening of the language in the risk clauses in the Informed Consent Document.
KOOL: 0.88 (-0.14)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
Cesca Therapeutics names Denis Michael Rhein to board
M2 - Mon Dec 08, 6:01AM CST
Medicine company Cesca Therapeutics (NasdaqCM:KOOL) said on Friday that Denis Michael Rhein has been elected to its board of directors.
KOOL: 0.88 (-0.14)
Cesca Therapeutics Appoints Mr. Denis Michael Rhein to Its Board of Directors
GlobeNewswire - Fri Dec 05, 4:59AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Denis Michael Rhein (54) has been appointed to the Company's Board of Directors.
KOOL: 0.88 (-0.14), DB: 32.29 (+0.70)
Cesca Therapeutics Invited to Present at LD Micro Conference and the World Stem Cell Summit
GlobeNewswire - Wed Nov 26, 5:24AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the LD Micro Conference on Tuesday, December 2nd and at the World Stem Cell Summit on Wednesday, December 3rd.
KOOL: 0.88 (-0.14)
Cesca up on IDE filing
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 2:50PM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb Ischemia ("CLI"
GlobeNewswire - Thu Nov 20, 5:34AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company developing proprietary devices and methods for cardiovascular, orthopedic and hematological/oncological procedures, today announced it has submitted an investigational device exemption ("IDE" application to the U.S. Food and Drug Administration ("FDA" for a pivotal multicenter study of the Company's SurgWerks-CLI and VXP System ("SURGWERKS-CLI" for treating advanced stages of no-option lower limb critical limb ischemia. The IDE application is the result of two prior positive pilot and feasibility studies conducted in Italy and India, respectively, and collaborative pre-IDE feedback from the U.S. FDA.
KOOL: 0.88 (-0.14)
Cesca Therapeutics' (KOOL) CEO Robin Stracey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 15, 12:39AM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics FQ2 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 9:24AM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics' (KOOL) on CEO Robin Stracey Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 8:37PM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:11PM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics Reports Second Quarter Fiscal 2015 Results
GlobeNewswire - Thu Feb 12, 3:00PM CST
Company to Provide an Update on the Status of Its IDE Submission to the FDA for a Phase III Pivotal Clinical Trial for the Treatment of Patients With Critical Limb Ischemia
KOOL: 0.88 (-0.14)
Cesca Therapeutics Announces Approval of Its MarrowXpress(TM) System in India
GlobeNewswire - Wed Feb 11, 9:56AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has received approval from the India Drug Controller General ("DCGI"
for the import and commercialization of its MarrowXpress ("MXP" System in India. KOOL: 0.88 (-0.14)
Cesca Therapeutics to Announce Second Quarter Fiscal 2015 Results on February 12, 2015
GlobeNewswire - Wed Feb 11, 9:56AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal second quarter ended December 31, 2014, on Thursday, February 12, 2015.
KOOL: 0.88 (-0.14)
Cesca Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 09, 8:30AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today that the Company will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
KOOL: 0.88 (-0.14)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.88 (-0.14), PSTI: 2.91 (+0.01)
Cesca Therapeutics to Present at Biotech Showcase in San Francisco on January 13, 2015
GlobeNewswire - Thu Jan 08, 5:00AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the Biotech Showcase(TM) 2015 on Tuesday, January 13th at 10:00 AM PT (1:00 PM ET).
KOOL: 0.88 (-0.14)
Time in the Market, Not Timing the Market: Featured Research on Rite Aid, American Homes 4 Rent, Perfect World, Foamix, and Cesca
PR Newswire - Mon Jan 05, 7:45AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Rite Aid (NYSE: RAD), American Homes 4 Rent (NYSE: AMH), Perfect World (NASDAQ: PWRD), Foamix (NASDAQ: FOMX), and Cesca (NYSE: KOOL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KOOL: 0.88 (-0.14), AMH: 16.58 (-0.10), FOMX: 9.01 (-0.03), PWRD: 18.95 (+0.02), RAD: 8.34 (+0.25)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 0.88 (-0.14), BLDP: 2.66 (-0.26), PBR: 6.98 (+0.44), LNCO: 12.30 (+0.28), KITE: 62.59 (+0.82), NRX: 6.67 (-0.14), LINE: 12.94 (+0.40), PWRD: 18.95 (+0.02), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Cesca not quite there on Phase 3 CLI trial application
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 6:14AM CST
KOOL: 0.88 (-0.14)
Cesca Receives Feedback From the FDA on Its Pivotal Investigational Device Exemption ("IDE"
Application for Treating Critical Limb Ischemia ("CLI" GlobeNewswire - Fri Jan 02, 4:59AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that it has received a letter from the U.S. Food and Drug Administration responding to the Company's investigational device exemption ("IDE"
application for its pivotal CLIRST III clinical trial. The IDE application, filed on November 20, 2014, sought approval to begin a pivotal, randomized, placebo-controlled study of 224 late stage CLI patients at up to 60 clinical sites in the United States and India. In its letter, the FDA noted several deficiencies in the Company's submission, requesting, among other things, additional information on characterization of the output of the SurgWerks(TM) - CLI and VXP system, a plan for testing device output for conformity to predefined intra-operative release criteria prior to administration, modifications to the management of potential adverse events and a strengthening of the language in the risk clauses in the Informed Consent Document. KOOL: 0.88 (-0.14)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
Cesca Therapeutics names Denis Michael Rhein to board
M2 - Mon Dec 08, 6:01AM CST
Medicine company Cesca Therapeutics (NasdaqCM:KOOL) said on Friday that Denis Michael Rhein has been elected to its board of directors.
KOOL: 0.88 (-0.14)
Cesca Therapeutics Appoints Mr. Denis Michael Rhein to Its Board of Directors
GlobeNewswire - Fri Dec 05, 4:59AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Denis Michael Rhein (54) has been appointed to the Company's Board of Directors.
KOOL: 0.88 (-0.14), DB: 32.29 (+0.70)
Cesca Therapeutics Invited to Present at LD Micro Conference and the World Stem Cell Summit
GlobeNewswire - Wed Nov 26, 5:24AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the LD Micro Conference on Tuesday, December 2nd and at the World Stem Cell Summit on Wednesday, December 3rd.
KOOL: 0.88 (-0.14)
Cesca up on IDE filing
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 2:50PM CST
KOOL: 0.88 (-0.14)
Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb Ischemia ("CLI"
GlobeNewswire - Thu Nov 20, 5:34AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company developing proprietary devices and methods for cardiovascular, orthopedic and hematological/oncological procedures, today announced it has submitted an investigational device exemption ("IDE"
application to the U.S. Food and Drug Administration ("FDA" for a pivotal multicenter study of the Company's SurgWerks-CLI and VXP System ("SURGWERKS-CLI" for treating advanced stages of no-option lower limb critical limb ischemia. The IDE application is the result of two prior positive pilot and feasibility studies conducted in Italy and India, respectively, and collaborative pre-IDE feedback from the U.S. FDA. KOOL: 0.88 (-0.14)
Cesca Therapeutics' (KOOL) CEO Robin Stracey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 15, 12:39AM CST
KOOL: 0.88 (-0.14)
